Price Isn't Enough: Sandoz Hones Biosimilars Strategy With Lessons From Omnitrope
Executive Summary
As FDA fleshes out the beginnings of a biosimilar regulatory pathway in the U.S., Novartis AG's generics business Sandoz is starting to draw important lessons in how to effectively commercialize copy-cat biologics.
You may also be interested in...
Biosimilar But Different: Zarxio, Neupogen Diverge On Syringes, Vials
Differences in product presentation may not have much market impact now but could prove a regulatory challenge if Sandoz pursues an interchangeability determination down the line.
Biosimilar Pricing: Sandoz Vows Not To Make Omnitrope ‘Mistake’ With Filgrastim
Sandoz, Hospira execs say U.S. payers and consumers will ‘not be disappointed’ in cost savings from products approved under the 351(k) pathway, but warn that price alone may not tell whole story.
Biosimilar Insulin: Why Novo Knows No Fear
Even after the largest pharmaceutical company in the sector, Pfizer Inc., announced it was laying a stake in the biosimilar insulin market, Danish diabetes leader Novo Nordisk A/S – about one-fifth the size of Pfizer in sales terms, although its market cap is just under half of Pfizer's – didn't flinch.